Table 1.

Relationship between NHERF1 expression and clinicopathological parameters

	Frequency (%)	NHERF1 (mean ± SE)	NHERF1 (median)	p (median)
Age				0.285
<55	22 (51.2)	1.8 ± 0.53	0.56
>55	21 (51.2)	2.77 ± 0.69	1.10
Menopausal status				0.740
Premenopause	15 (23.03)	2.2 ± 0.7	0.59
Postmenopause	28 (65.1)	2.3 ± 0.54	0.80
Tumor size				0.625
≤2 cm	10 (31.25)	1.69 ± 0.51	0.87
≥2 cm	22 (68.75)	2.04 ± 0.65	0.58
Node status				0.078
Negative (N0)	23 (53.5)	1.46 ± 0.39	0.51
Positive (N1-2)	20 (46.5)	3.02 ± 0.79	0.80
Grade				0.028
1	6 (15.4)	0.41 ± 0.13	0.41
2	16 (41)	1.51 ± 0.49	0.66
3	17 (43.6)	3.39 ± 0.72	3.14
NPI				0.031
<2.5	6 (14)	0.40 ± 0.2	0.2
2.5–3.5	19 (44.2)	0.95 ± 0.3	0.71
>3.5	18 (41.9)	4.62 ± 1.4	5.09
MIB				0.920
Positive	28 (65.12)	2.19 ± 0.48	0.79
Negative	15 (34.88)	2.46 ± 0.89	0.62
ER				0.315
Positive	18 (50)	1.85 ± 0.48	0.79
Negative	18 (50)	2.78 ± 0.78	0.95
PgR				0.089
Positive	17 (46)	1.44 ± 0.44	0.51
Negative	24 (58.54)	2.92 ± 0.65	1.15

NHERF1 expression measured in Western blot was relative to expression in identical extracts of MCF-7 cells. n = 43 invasive ductal breast carcinomas (median age 55). Significance between median NHERF1 expression values for grade and NPI were evaluated by the Kruskal–Wallis nonparametric analysis of variance test, whereas the Mann–Whitney nonparametric test was applied to age, menopausal status, size, MIB, node status, and receptor status.